<DOC>
	<DOC>NCT00150813</DOC>
	<brief_summary>An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.</brief_summary>
	<brief_title>Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy, Tonic-Clonic</mesh_term>
	<mesh_term>Epilepsy, Generalized</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects with a confirmed diagnosis of epilepsy. Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin),or generalized tonicclonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures Subjects having participated in the previous doubleblind monotherapy trial (N01061 or N01093). Male/female subjects (â‰¥ 16 years). Need for an additional AED.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Monotherapy, epilepsy</keyword>
	<keyword>Keppra, levetiracetam</keyword>
</DOC>